Cohort Studyhigh evidence
Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.
BMJ (Clinical research ed.)·March 4, 2026·PMID 41781010
Why it mattersThese findings suggest GLP-1 receptor agonists may have a broad preventive and therapeutic effect on substance use disorders, which are common and challenging in pain populations. This could influence medication selection in patients with comorbid diabetes and pain or addiction risk.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled